Allied Market Research Unveils Study on Booming Graft Versus Host Disease Market, Projected to Surpass $10.4 Billion by 2031 with 13.5% CAGR

𝘛𝘩𝘦 𝘨𝘭𝘰𝘣𝘢𝘭 𝘨𝘳𝘢𝘧𝘵 𝘷𝘦𝘳𝘴𝘶𝘴 𝘩𝘰𝘴𝘵 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘮𝘢𝘳𝘬𝘦𝘵 𝘪𝘴 𝘥𝘳𝘪𝘷𝘦𝘯 𝘣𝘺 𝘵𝘩𝘦 𝘳𝘪𝘴𝘪𝘯𝘨 𝘨𝘦𝘳𝘪𝘢𝘵𝘳𝘪𝘤 𝘱𝘰𝘱𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘪𝘯𝘤𝘳𝘦𝘢𝘴𝘪𝘯𝘨 𝘱𝘳𝘦𝘷𝘢𝘭𝘦𝘯𝘤𝘦 𝘰𝘧 𝘯𝘦𝘱𝘩𝘳𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘤𝘰𝘯𝘥𝘪𝘵𝘪𝘰𝘯𝘴, 𝘭𝘦𝘶𝘬𝘦𝘮𝘪𝘢, 𝘮𝘺𝘦𝘭𝘰𝘮𝘢, 𝘢𝘯𝘥 𝘭𝘺𝘮𝘱𝘩𝘰𝘮𝘢.

Allied Market Research released a report titled “Graft Versus Host Disease Market by Product Type (Corticosteroids, Monoclonal Antibodies, Immunosuppressants, Others), by Treatment Type (Acute GVHD, Chronic GVHD), by End Use (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031.” The report states that the global graft versus host disease market, valued at $3.0 billion in 2021, is projected to reach $10.4 billion by 2031, with a CAGR of 13.5% from 2022 to 2031.

Prime Determinants of Growth:

The global graft versus host disease market is driven by a surge in the geriatric population and an increase in the prevalence of nephrological conditions, leukemia, myeloma, and lymphoma. Additionally, the rise in bone marrow transplants worldwide to treat specific cancers has further propelled market growth. Simultaneously, the increasing prevalence of GVHD, advancements in diagnostic methods, approval of novel treatments, and a wider range of prophylaxis options are expected to create lucrative opportunities in the industry.

Download Sample Report- https://www.alliedmarketresearch.com/request-sample/12294

The Acute GVHD Segment to Dominate by 2031:

By treatment type, the acute GVHD segment accounted for nearly three-fifths of the global graft versus host disease market share in 2021 and is projected to lead by 2031. This segment is also expected to exhibit the fastest CAGR of 5.8% from 2022 to 2031, driven by the rising geriatric population and the increase in allogeneic transplantations.

The Hospital Pharmacies Segment to Maintain the Lion’s Share:

By end-use, the hospital pharmacies segment contributed to more than two-fifths of the global graft versus host disease market revenue in 2021 and is expected to continue dominating by 2031, due to the high demand for transplantation drugs. Meanwhile, the online pharmacies segment is projected to grow at the fastest CAGR of 14.0% during the forecast period, driven by the shift in buying patterns towards online pharmacies amid the Covid-19 pandemic.

North America Garnered the Major Share in 2021:

By region, North America held more than two-fifths of the global graft versus host disease market share in 2021, attributed to the increase in organ donations from deceased persons, rise in allogeneic transplantation procedures, and a surge in cancer patients. The Asia-Pacific region is expected to register the fastest CAGR of 15.9% throughout the forecast period, due to the growing demand for drugs like corticosteroids and monoclonal antibodies across the region.

For Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/12294

Key players in the industry-

• Asahi Kasei
• AbbVie
• Bristol Myer Squibb
• GlaxoSmithKline PLC
• Sanofi.
• Incyte Corporation
• Pfizer
• Accord Healthcare Limited
• Merck & Co
• Novartis

Official Press Release- https://www.alliedmarketresearch.com/press-release/graft-versus-host-disease-market.html